Skip to Content

Melphalan Pregnancy and Breastfeeding Warnings

Melphalan is also known as: Alkeran, Evomela

Medically reviewed on October 6, 2017.

Melphalan Pregnancy Warnings

Melphalan has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of embryolethality and teratogenicity. There are no controlled data in human pregnancy. Melphalan has been reported to cause suppression of ovarian function in premenopausal women, resulting in amenorrhea in a significant number of patients. Both reversible and irreversible testicular suppression have also been reported. Melphalan should only be given during pregnancy when there are no alternatives and benefit outweighs risk. If this drug is used during pregnancy or if the patient becomes pregnant while receiving the drug, she should be made aware of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

See references

Melphalan Breastfeeding Warnings

There are no data on the excretion of melphalan into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions due to melphalan in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.

References for breastfeeding information

  1. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide